In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Chong LiCancer Institute, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Research and Development Department, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 200032, China.ORCID 0000-0001-7988-3069 Xueyang LiuCancer Institute, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Research and Development Department, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 200032, China.ORCID 0009-0009-2472-3012 Lin ZhuCancer Institute, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Research and Development Department, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 200032, China.ORCID 0009-0007-1402-0108 Ming LiuDepartment of Radiation Oncology, Shanghai Pulmonary Hospital School of Medicine Tongji University, Shanghai 200433, China.ORCID 0000-0001-9466-5203 Teruaki KonishiDepartment of Radiation Regulatory Science Research, Institute for Radiological Science, National Institutes for Quantum Science and Technology (QST), Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-2485-9659 Xiaokun LouCancer Institute, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Research and Development Department, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 200032, China.
Li ChenShanghai Key Laboratory of Radiation Oncology, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.ORCID 0009-0004-5355-0644 Jiatao LiaoCancer Institute, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Research and Development Department, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 200032, China.ORCID 0000-0002-0449-3530 Yirui HongCancer Institute, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Research and Development Department, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 200032, China.
Yun DengCancer Institute, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Research and Development Department, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 200032, China.ORCID 0009-0003-3003-0059 Mei XiaoShanghai Key Laboratory of Radiation Oncology, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.
Chunlin ShaoShanghai Key Laboratory of Radiation Oncology, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.ORCID 0000-0001-9336-9912 Lin KongShanghai Key Laboratory of Radiation Oncology, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.ORCID 0009-0002-5544-7873 Xiaomao GuoShanghai Key Laboratory of Radiation Oncology, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.ORCID 0000-0002-8700-982X Fengtao SuCancer Institute, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Research and Development Department, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 200032, China.ORCID 0000-0003-1836-4606 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Radiotherapy augments immunotherapy, yet conventional 2 Gy x-ray fractions largely induce apoptosis, whereas robust immunogenic cell death (ICD) is more commonly associated with higher-dose irradiation regimens. Here, we reveal a dose-independent, high-LET-specific paradigm: a physical dose of 2 Gy of carbon ions provokes antitumor immunity. Carbon ions redirect death wiring to MLKL-dependent necroptosis and trigger an NF-κB-driven inflammatory cascade (IL1A/B, CXCL1/2/3), surpassing 8 Gy x-rays in immunogenicity despite lower direct tumor cell-killing capacity. Multi-omics analyses identify clustered DNA damage-driven super-enhancer remodeling as an epigenetic switch that suppresses cIAP1/2-caspase-8-mediated apoptosis while licensing inflammatory necroptosis. Pharmacologic inhibition of MLKL abolishes these responses to carbon ion radiotherapy (CIRT). In vivo, 2 Gy CIRT drives abscopal response with increased CD8
Indexed as
Heavy Ion RadiotherapyNecroptosisSuper EnhancersAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansMice
Identifiers
PMID42647624
PMCPMC13510677
What OpenQuestion holds
Textmetadata
Read underepoch 390